In a unanimous decision issued on February 19, 2013, the U.S. Supreme Court ruled that the state-action doctrine did not immunize Phoebe Putney Health System’s acquisition of Palmyra Park Hospital in Albany, Georgia.1 The decision immediately was hailed by FTC Chairman Jon Leibowitz as “a big victory for consumers who want to see lower health care costs” and one that “will ensure competition in a variety of other industries, as well.” This ruling both clarifies the standards needed to establish state-action immunity, while raising questions about what evidence will meet these standards.
Phoebe arose out of the merger between two hospitals, Phoebe Putney Memorial Hospital (PPMH) and Palmyra Medical Center (Palmyra). PPMH was owned by the Hospital Authority of Albany-Dougherty (the Authority), which leased PPMH to Phoebe Putney Health System (PPHS), a private nonprofit corporation that operated the hospital. Palmyra, the second of the two hospitals in Dougherty County, was operated by a national for-profit hospital network, HCA, Inc. (HCA). In 2010, PPHS began discussions with HCA regarding the possible acquisition of Palmyra. Because of financing and antitrust concerns, PPHS proposed a transaction structure whereby the Authority would purchase Palmyra and lease it to a PPHS subsidiary. The Authority approved the transaction in 2011, and the FTC filed suit to enjoin the transaction shortly thereafter, alleging that the merger would result in a virtual monopoly in the market for acute care hospital services in the six counties surrounding Albany. The district court denied the request for a preliminary injunction, holding that the transaction was immune from antitrust liability under the state-action doctrine. The U.S. Court of Appeals for the Eleventh Circuit affirmed.2
The Supreme Court overturned, holding that the state-action doctrine did not provide immunity from the antitrust laws “because there is no evidence the State affirmatively contemplated that hospital authorities would displace competition by consolidating hospital ownership.” Prior precedent established that for state-action immunity to apply, the anticompetitive effect must be the foreseeable result of what the state authorized. Here, the Court found no evidence that the Georgia legislature “affirmatively contemplated that hospital authorities would displace competition by consolidating hospital ownership.” While the Georgia law that established hospital authorities as special-purpose public entities granted those entities broad general corporate powers, including the power to acquire hospitals, the Court found that it did not “clearly articulate and affirmatively express a state policy empowering the Authority to make acquisitions of existing hospitals that will substantially lessen competition.”
Going forward, the Court’s test will require analyzing whether a given state statute “clearly articulat[es] an affirmative state policy to displace competition with a regulatory alternative,” in which case the state-action doctrine may apply. And, as the Court explained, a statutory construct that provides for the general regulation of an industry, and even authorizes some discrete forms of anticompetitive conduct, is not enough to establish that the state affirmatively contemplated other tangentially related forms of anticompetitive conduct.3 The Court expressed concern that a rule allowing loose application of the clear-articulation test would require states to affirmatively disclaim any intent to displace competition to avoid inadvertently authorizing anticompetitive conduct. However, the Court’s decision leaves open the question of exactly what will qualify as a clearly articulated affirmative expression such that immunity will apply.
The Phoebe decision is a significant win for the FTC, which has challenged several recent hospital deals. Outgoing Chairman Leibowitz emphasized enforcement in the health care sector as one of his priorities during his tenure and had argued that if the Phoebe deal was allowed to proceed it would not only drive up costs to consumers in Albany, Georgia, but it also would “create a roadmap for doing so elsewhere.”4 This decision raises the bar for health care organizations, as well as other types of entities, looking for immunity from the antitrust laws by way of the state-action doctrine. As financial pressures rise for hospitals and drive consolidation of facilities to achieve efficiencies of scale, this ruling will require state legislatures to affirmatively act if antitrust laws are not to impede those efforts in some markets.
1 FTC v. Phoebe Putney Health System, Inc., 568 U.S. __ (2013).
2 Id. See also FTC v. Phoebe Putney Health System, Inc., 663 F.3d 1369 (11th Cir. 2011); FTC v. Phoebe Putney Health System, Inc., 793 F. Supp. 2d 1356 (M.D. Ga. 2011).
3 Phoebe Putney, 568 U.S. __.
4 Remarks of FTC Chairman Jon Leibowitz, Antitrust in Healthcare Conference American Bar Asociation/American Health Lawyers Association, “Are Titanic Health Care Costs Sinking Us? What the FTC Is Doing to Keep Patients Afloat,” at 5 (May 3, 2012).
This memorandum is provided by Skadden, Arps, Slate, Meagher & Flom LLP and its affiliates for educational and informational purposes only and is not intended and should not be construed as legal advice. This memorandum is considered advertising under applicable state laws.